Overview

Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS)

Status:
Completed

Trial end date:
2016-10-18

Target enrollment:

Participant gender:

Summary

Our main objectives are to determine the optimal dose and schedule of plerixafor + G-CSF and azacitidine in patients with MDS and determine the safety and tolerability of plerixafor + G-CSF and azacitidine.

Phase:

Phase 1

Details

Lead Sponsor:

Washington University School of Medicine

Treatments:

Azacitidine
JM 3100
Lenograstim
Plerixafor